VolitionRx Limited has completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q Vet Cancer Test in collaboration with Fujifilm Vet Systems Co. Ltd in Japan, enabling the test to be run through fully automated systems in central laboratories instead of manual plates.

The automation allows laboratories to process the test using the IDS i10 automated analyzer platform, enabling faster turnaround times and higher testing volumes to meet growing demand from veterinary clinics.

Since the test’s launch in Japan in July 2024, interest among veterinarians has grown significantly, with more than 1,700 veterinary hospitals already registered to use the screening tool. The new automated version is expected to further expand adoption by improving efficiency in diagnostic laboratories.

Japan has an estimated seven million pet dogs, presenting a sizeable market for veterinary diagnostics. Cancer remains the leading cause of death in adult dogs, and earlier detection can significantly improve treatment outcomes.

Under an existing supply agreement, Fujifilm Vet Systems will distribute and perform the Nu.Q Vet Cancer Test through its network of central reference laboratories across Japan, which collectively serve around 11,000 veterinary medical facilities.

The automated platform used for the veterinary test is also employed for Volition’s human diagnostic products, including Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover, highlighting the broader potential of the company’s epigenetics-based diagnostic technology across both human and animal healthcare.